Abacavir is a human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor indicated for the treatment of human immunodeficiency virus (HIV-1) infection. It is available as tablets, oral solution and kits. MedsAcross supplies Abacavir for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ZIAGEN tablets and oral solution, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (HIV-1) infection. ZIAGEN, a nucleoside analogue human immunodeficiency virus (HIV-1) reverse transcriptase inhibitor, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Source: US FDA prescribing information
Abacavir is an antiretroviral agent.
Source: US FDA prescribing information
• Before initiating ZIAGEN, screen for the HLA-B*5701 allele. • Adults: 600 mg daily, administered as either 300 mg twice daily or 600 mg once daily. • Pediatric Patients Aged 3 Months and Older: Administered either once or twice daily. Dose should be calculated on body weight (kg) and should not exceed 600 mg daily. • Patients with Hepatic Impairment: Mild hepatic impairment – 200 mg twice daily.
Source: US FDA prescribing information
ZIAGEN is contraindicated in patients: • who have the HLA‑B*5701 allele. • with prior hypersensitivity reaction to abacavir. • with moderate or severe hepatic impairment. • Presence of HLA-B*5701 allele. • Prior hypersensitivity reaction to abacavir. • Moderate or severe hepatic impairment.
Source: US FDA prescribing information
Boxed warning (hypersensitivity reactions): Serious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with ZIAGEN (abacavir). Patients who carry the HLA ‑ B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir, although, hypersensitivity reactions have occurred in patients who do not carry the HLA ‑ B*5701 allele. • Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues. • Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy.
Source: US FDA prescribing information
The following adverse reactions are discussed in other sections of the labeling: • Serious and sometimes fatal hypersensitivity reactions. • Lactic acidosis and severe hepatomegaly with steatosis. • Immune reconstitution syndrome. • Myocardial infarction. • The most commonly reported adverse reactions of at least moderate intensity (incidence greater than or equal to 10%) in adult HIV-1 clinical trials were nausea, headache, malaise and fatigue, nausea and vomiting, and dreams/sleep disorders. • The most commonly reported adverse reactions of at least moderate intensity (incidence greater than or equal to 5%) in pediatric HIV-1 clinical trials were fever and/or chills, nausea and vomiting, skin rashes, and ear/nose/throat infections.
Source: US FDA prescribing information
• Methadone: An increased methadone dose may be required in a small number of patients. • Riociguat: The riociguat dose may need to be reduced.
Source: US FDA prescribing information
Store at controlled room temperature of 20° to 25°C (68° to 77°F). DO NOT FREEZE. May be refrigerated.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
4 presentations of Abacavir, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Abacavir 300 mg tabletOralGeneric name | — | US FDA | Available on request |
| Abacavir 20 mg/mL oral solutionOral Cold chainGeneric name | — | US FDA | Available on request |
| Triumeq PD kit | ViiV Healthcare | US FDA | Available on request |
| Ziagen 20 mg/mL oral solutionOral Cold chain | ViiV Healthcare | US FDA | Available on request |
2 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Abacavir in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 4 presentations of Abacavir and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Abacavir, including Triumeq PD, Ziagen.
Yes. The US FDA first approved Abacavir on 17 December 1998, according to Drugs@FDA.
Yes. Abacavir has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Abacavir must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Abacavir is classified under ATC code J05AF06 (Abacavir).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.